
    
      Primary objective:

      - To evaluate the occurrence of grade 4 neutropenia during weekly paclitaxel/carboplatin with
      prophylactic G-CSF

      Secondary objectives:

        -  To evaluate per cohort the occurrence of grade 4 neutropenia

        -  To evaluate other toxicities

        -  To evaluate the dose reductions or dose delays in the chemotherapy

        -  To determine the progression free survival according to RECIST v1.1

        -  To evaluate the response rate and overall survival
    
  